Median Effective Dose of Propofol Combined with Different Doses of Oxycodone for Painless Gastroscopy in Adults

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500104516

Enrollment

Unknown

Registered

2025-06-18

Start date

2025-07-15

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

N1 Group:Intravenous administration of oxycodone 0.05 mg/kg

N2 Group:Intravenous administration of oxycodone 0.075 mg/kg

N3 Group:Intravenous administration of oxycodone 0.1 mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for painless gastroscopy, meeting the following criteria: 2. Gender: No restriction 3. Age: 18–60 years 4. ASA physical status: I or II 5. BMI: 18–24 kg/m²

Exclusion criteria

Exclusion criteria: 1. Hepatic or renal dysfunction; 2. Severe cardiovascular/cerebrovascular diseases, acute/chronic respiratory diseases, or obstructive sleep apnea syndrome; 3. History of psychiatric disorders, cognitive impairment, or abuse of sedatives/analgesics; 4. Allergy to study medications (propofol, oxycodone, etc.); 5. Gastroscopy duration >30 minutes; 6. Inability to provide informed consent.

Design outcomes

Primary

Measure	Time frame
Median effective dose (ED50);Dosage of Propofol;Oxycodone dosage;	—

Secondary

Measure	Time frame
Onset time;Recovery time;Time to recovery of orientation;Duration of procedure;Respiratory depression;Hypotension;Adverse reactions;	—

Countries

China

Contacts

Public ContactYang Fangfang

People's Hospital of Fuyang City

18255363858@163.com+86 182 5536 3858

Outcome results